TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07100249: A Phase Ia/Ib Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of HDM2012 in Subjects With Advanced Solid Tumors

Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 129 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07100249 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07100249 Rescue Dossier →